2024
Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
Taylor J, Kamat A, O'Donnell M, Annapureddy D, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International 2024 PMID: 39183466, DOI: 10.1111/bju.16509.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder-sparing therapyUpfront RCRadical cystectomyCohort of patientsBladder cancerBCG-unresponsive NMIBCRetrospective cohort of patientsProgression to MIBCUpfront radical cystectomyCancer-specific survivalInstitutional review board approvalMetastasis-free survivalFood and Drug Administration criteriaRate of recurrenceReview board approvalLong-term outcomesStatistically significant differenceNodal diseaseRe-resectionSystemic immunotherapyIntravesical chemotherapyOncological outcomesOverall survivalOncological riskONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Annapureddy D, Taylor J, Howard J, Woldu S, Lotan Y, Tan W, Kamat A, McElree I, Packiam V, O'Donnell M, Facundo D, Li R, Yim K, Preston M, Harrington S, Dyer E, Raman J, Black A, Black P, Kanabur P, Lerner S, Roumiguié M, Steinberg G, Huang W. ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER. Urologic Oncology Seminars And Original Investigations 2024, 42: s52-s53. DOI: 10.1016/j.urolonc.2024.01.160.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBladder-sparing therapyBCG-unresponsive diseaseBCG-unresponsive NMIBCMultinational cohort of patientsUpfront RCCancer-specific survivalInvasive bladder cancerRadical cystectomyOncological outcomesCohort of patientsAdequate BCGBCG therapyBCG-unresponsiveSalvage therapySpecific survivalBladder cancerMultinational cohortBCG-unresponsive NMIBC patientsAdequate BCG therapyBladder sparing therapyCombination intravesical therapyMaintenance BCG therapyNode positivity rateCompare oncologic outcomesNATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORT
Taylor J, Annapureddy D, Howard J, Woldu S, Lotan Y, Tan W, Kamat A, McElree I, Packiam V, O'Donnell M, Davaro F, Li R, Yim K, Preston M, Harrington S, Dyer E, Raman J, Black A, Black P, Kanabur P, Lerner S, Roumiguié M, Steinberg G, Huang W. NATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORT. Urologic Oncology Seminars And Original Investigations 2024, 42: s49. DOI: 10.1016/j.urolonc.2024.01.152.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBCG-unresponsive NMIBCBladder-sparing therapyBCG-unresponsive diseaseBCG-unresponsiveRate of cystectomyCohort of patientsOncological outcomesRadical cystectomyBladder cancer deathAdequate BCGBCG therapyOncological riskCancer deathRetrospective multi-center cohortInternational cohort of patientsAdequate BCG therapyAlternative intravesical agentsIntravesical mitomycin CMaintenance BCG therapyNatural historyUpfront radical cystectomyInferior oncologic outcomesMulti-center cohort of patientsUpper tract diseaseAssociation of Age with Non–muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?
Lobo N, Duan Z, Sood A, Tan W, Grajales V, Contieri R, Lindskrog S, Dyrskjøt L, Zhao H, Giordano S, Williams S, Bree K, Kamat A. Association of Age with Non–muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities? European Urology Oncology 2024, 7: 1069-1079. PMID: 38302322, DOI: 10.1016/j.euo.2024.01.011.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder cancer-specific mortalitySEER-Medicare dataSEER-MedicareAge disparitiesTumor biologyAdequate cancer careEnd Results (SEER)-MedicareSEER-Medicare cohortBladder cancerUROMOL cohortOncological outcomesMultivariate general linear modelCancer-specific mortalitySEER-Medicare patientsMultinomial logistic regressionAssociation of ageAssociated with inferior oncological outcomesCompeting-risks regressionCancer careAdvanced ageT1 non-muscle-invasive bladder cancerHigh risk of recurrenceClinical stage TaMultivariable competing-risks regression
2023
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile
Grajales V, Contieri R, Tan W, Flores M, Schultz M, Pinochet R, Bustamante A, Kamat A, Fernández M. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. Bladder Cancer 2023, 9: 327-334. PMID: 38994240, PMCID: PMC11165921, DOI: 10.3233/blc-230047.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBacillus Calmette-GuerinBacillus Calmette-Guerin treatmentHR-NMIBC patientsInvasive bladder cancerOncological outcomesHigh riskBladder cancerHigh-risk non-muscle invasive bladder cancerPatients treated with bacillus Calmette-GuerinAdjuvant bacillus Calmette-GuerinBacillus Calmette-Guerin instillationsFull doseFD groupMultivariate Cox regression modelCalculate survival estimatesReduced-dose regimensMedian follow-upRecurrence free rateKaplan-Meier methodReduced toxicity profileCox regression modelsHR-NMIBCStratify patientsRetrospective studyOncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian follow-upInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removalImpact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin
Contieri R, Grajales V, Tan W, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras‐Gonzalez G, Guo C, Navai N, Dinney C, Kamat A. Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin. BJU International 2023, 133: 63-70. PMID: 37442564, PMCID: PMC10787034, DOI: 10.1111/bju.16127.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinCancer-specific mortalityCompeting-risk regression analysisCohort of patientsOncological outcomesFood and Drug AdministrationHG recurrenceAssociated with adverse oncologic outcomesHigh-gradeImpact of ageInstitutional review board-approved retrospective studyBacillus Calmette-Guerin instillationsIntravesical BCGCumulative incidence of progressionAdverse oncologic outcomesIncidence of progressionAssociation of advanced ageUnited States Food and Drug AdministrationStates Food and Drug AdministrationCumulative incidence methodPredictors of progressionStudy's primary outcomeBCG instillationRegression analysisSequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
Tan W, McElree I, Davaro F, Steinberg R, Bree K, Navai N, Dinney C, O'Donnell M, Li R, Kamat A, Packiam V. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology 2023, 6: 531-534. PMID: 37468392, DOI: 10.1016/j.euo.2023.06.011.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinIntermediate-risk non-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancerIntermediate-riskMulti-institutional retrospective reviewBlue light cystoscopyCombination of docetaxelEvaluate oncological outcomesHigh-grade diseaseMedian follow-upCancer-specific mortalityTreatment groupsCancer control outcomesBladder cancer groupSequential gemcitabineChemotherapy combinationsOncological outcomesIntravesical gemcitabinePostoperative chemotherapyAdjuvant treatmentRetrospective reviewRecurrence rateCancer groupA0607 T1 substaging is associated with worse oncological outcomes for patients treated with Bacillus Calmette-Guerin or immediate radical cystectomy
Contieri R, Tan W, Grajales V, Bree K, Hensley P, Guo C, Navai N, Dinney C, Kamat A. A0607 T1 substaging is associated with worse oncological outcomes for patients treated with Bacillus Calmette-Guerin or immediate radical cystectomy. European Urology 2023, 83: s865. DOI: 10.1016/s0302-2838(23)00653-x.Peer-Reviewed Original Research
2022
Organ‐sparing radical cystectomy: improving functional outcomes
Tan W, Ta A, Sridhar A, Kelly J. Organ‐sparing radical cystectomy: improving functional outcomes. Trends In Urology & Men's Health 2022, 13: 7-10. DOI: 10.1002/tre.875.Peer-Reviewed Original Research
2021
Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Frontiers In Surgery 2021, 8: 775527. PMID: 34888347, PMCID: PMC8649716, DOI: 10.3389/fsurg.2021.775527.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerInvasive bladder cancerOncological outcomesSafety profileBladder cancerAdverse eventsMeta-analysisBacillus Calmette-Guerin instillationsHigh-risk NMIBC patientsIntravesical bacillus Calmette-GuerinMeta-analysis of clinical studiesBCG maintenance therapySystematic reviewMonths recurrence rateCochrane RoB toolCertainty of evidenceRisk of biasComprehensive literature searchBCG shortageChemotherapy maintenanceNMIBC patientsBCG treatmentMaintenance therapyRecurrence rate1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. 1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. British Journal Of Surgery 2021, 108: znab259.955. DOI: 10.1093/bjs/znab259.955.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerRecurrence-free survivalProgression-free survivalInvasive bladder cancerCarcinoma in situChemo-hyperthermiaAdverse eventsChemotherapy instillationSafety profileBladder cancerBCG groupBCG maintenance therapyTrans-urethral resectionMeta-analysisMonths recurrence rateSystematic reviewComprehensive literature searchQuality of evidenceBCG failureBCG shortageMaintenance therapyOncological outcomesRandomised controlled trialsRecurrence rateEffects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis
Chan V, Tan W, Asif A, Ng A, Gbolahan O, Dinneen E, To W, Kadhim H, Premchand M, Burton O, Koe J, Wang N, Leow J, Giannarini G, Vasdev N, Shariat S, Enikeev D, Ng C, Teoh J. Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis. Cancers 2021, 13: 3274. PMID: 34208888, PMCID: PMC8268689, DOI: 10.3390/cancers13133274.Peer-Reviewed Original ResearchNeoadjuvant hormonal therapyDelayed radical prostatectomyHigh-risk patientsRandomised controlled trialsRadical prostatectomyImmediate RPOncological outcomesCancer-specific survivalIntermediate-risk patientsMeta-analysisNewcastle-Ottawa ScaleDelayed RPIntermediate-riskNon-randomised controlled studiesRisk of biasOverall survivalHormone therapyWatchful waitingExpectant managementActive surveillanceCancer surgeryPathological outcomesNewcastle-OttawaLow riskObservational study
2020
776 Intravesical chemohyperthermia (HIVEC-E) in BCG unresponsive non-muscle invasive bladder cancer patients: Oncological outcomes of a multi-centre European registry
Tan W, Chiancone F, Fedelini P, Boormans J, De Jong J, Wilby D, Robinson R, Poggio M, Escudero J, Goizueta F, Plata A, Vögeli T, Escandón A, Nzeh C, De La Morena J, Moreno J, Guerrero F, Torres J, Hendricksen K. 776 Intravesical chemohyperthermia (HIVEC-E) in BCG unresponsive non-muscle invasive bladder cancer patients: Oncological outcomes of a multi-centre European registry. European Urology Open Science 2020, 19: e1181-e1182. DOI: 10.1016/s2666-1683(20)33376-0.Peer-Reviewed Original Research
2017
The Role of Robotics in the Invasive Management of Bladder Cancer
Khetrapal P, Tan W, Lamb B, Tan M, Baker H, Thompson J, Sridhar A, Kelly J, Briggs T. The Role of Robotics in the Invasive Management of Bladder Cancer. Current Urology Reports 2017, 18: 57. PMID: 28634646, DOI: 10.1007/s11934-017-0706-7.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyRobot-assisted laparoscopic prostatectomyRadical cystectomyUrinary reconstructionIntracorporeal robot-assisted radical cystectomyManagement of bladder cancerOpen radical cystectomySurgical learning curveBladder cancer surgeryEnhanced recovery programmeComparison of outcomesLaparoscopic prostatectomyOncological outcomesIleus ratesBladder cancerCancer surgeryPerioperative measuresOpen techniqueInvasive managementShort recovery periodRobotic approachImprove outcomesPatient outcomesReduce recovery timeCystectomyA Comprehensive Guide to Perioperative Management and Operative Technique for Robotic Cystectomy with Intracorporeal Urinary Diversion
Tan W, Lamb B, Sridhar A, Briggs T, Kelly J. A Comprehensive Guide to Perioperative Management and Operative Technique for Robotic Cystectomy with Intracorporeal Urinary Diversion. Urologia Journal 2017, 84: 71-78. PMID: 28256704, DOI: 10.5301/uj.5000224.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical cystectomyOpen radical cystectomyConversion to open surgeryReturn to normal functionOncological outcomesRadical cystectomyOpen surgeryUrinary diversionEarly return to normal functionLack of level 1 evidenceShort-term oncological outcomesHigh-volume centresLevel 1 evidenceMinimally invasive approachReduce patient morbidityIntracorporeal urinary diversionEnhanced recovery protocolEarly surgical experienceHigh-volume experienceNormal functionRobotic cystectomyOncologic equivalencePerioperative complicationsPatient selectionInvasive approach
2016
Analysis of open and intracorporeal robotic assisted radical cystectomy shows no significant difference in recurrence patterns and oncological outcomes
Tan W, Sridhar A, Ellis G, Lamb B, Goldstraw M, Nathan S, Hines J, Cathcart P, Briggs T, Kelly J. Analysis of open and intracorporeal robotic assisted radical cystectomy shows no significant difference in recurrence patterns and oncological outcomes. Urologic Oncology Seminars And Original Investigations 2016, 34: 257.e1-257.e9. PMID: 26968561, DOI: 10.1016/j.urolonc.2016.02.010.Peer-Reviewed Original ResearchConceptsRecurrence free survivalCancer-specific survivalOpen radical cystectomyORC cohortOverall survivalRadical cystectomySpecific survivalNo significant differenceOncological outcomesSignificant differenceOpen radical cystectomy casesPositive surgical margin rateIntracorporeal robot-assisted radical cystectomyRobotic-assisted radical cystectomyRobot-assisted radical cystectomyEarly oncologic outcomesPreoperative chemotherapy useSurgical margin rateLymph node yieldMedian follow-upKaplan-Meir analysisCox regression analysisIntracorporeal urinary diversionRecurrence patternsPT0 status
2015
Robot‐assisted intracorporeal pyramid neobladder
Tan W, Sridhar A, Goldstraw M, Zacharakis E, Nathan S, Hines J, Cathcart P, Briggs T, Kelly J. Robot‐assisted intracorporeal pyramid neobladder. BJU International 2015, 116: 771-779. PMID: 26033321, DOI: 10.1111/bju.13189.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyMuscle-invasive bladder cancerUrinary tract infectionPostoperative complicationsFunctional outcomesMedian estimated blood lossNight time continenceBilateral pelvic lymphadenectomyEstimated blood lossMedian hospital stayRecurrence-free survivalUpper tract imagingMedian follow-upLate postoperative complicationsEarly postoperative complicationsPort-site herniaUretero-ileal strictureVitamin B12 deficiencyBlocked stentsNeobladder stonePelvic lymphadenectomyOncological outcomesRadical cystectomyOverall survivalBlood loss